Huzursuz Bacaklar Sendromu
Özet
Huzursuz Bacaklar Sendromu (HBS), özellikle dinlenme dönemlerinde ve akşam saatlerinde bacaklarda ortaya çıkan rahatsız edici hisler ve buna bağlı gelişen kontrol edilemez hareket ettirme dürtüsü ile karakterize, uyku kalitesini ve günlük yaşamı olumsuz etkileyen yaygın bir nörolojik hareket bozukluğudur. Tanısı temelde hastanın klinik öyküsüne ve uluslararası çalışma grubunun belirlediği beş temel kriter ile laboratuvar testlerine dayanarak ikincil nedenlerin dışlanmasına dayanmaktadır. Tedavi süreci hastalığın şiddetine göre şekillenmekte olup; hafif vakalarda kafein kısıtlaması, uyku hijyeni ve egzersiz gibi farmakolojik olmayan yaşam tarzı değişiklikleri yeterli olabilirken, orta ve şiddetli vakalarda dopaminerjik ajanlar, alfa-2-delta kalsiyum kanal ligandları ve opioidler içeren ilaç tedavileri tercih edilmektedir. Ancak semptomları hafifletmeye yönelik bu kronik ilaç kullanımlarında, hastalığın doz artışıyla paradoksal olarak kötüleşmesi anlamına gelen "augmentasyon" (şiddetlenme), sabah saatlerinde şikayetlerin tekrarlaması (rebound) ve dürtü kontrol bozuklukları gibi önemli yan etkiler gelişebileceğinden, tedavinin hastanın yaşına, ek hastalıklarına ve minimum dozaj ayarlamalarına göre bireyselleştirilmesi kritik önem taşır.
Restless Legs Syndrome (RLS) is a common neurological movement disorder characterized by an uncontrollable urge to move the legs, accompanied by uncomfortable sensations that primarily occur during rest and in the evening, significantly impairing sleep quality and daily life. Its diagnosis is fundamentally based on the patient's clinical history, the five core criteria established by the international study group, and laboratory tests to exclude secondary causes. The treatment process is tailored to the severity of the disease; while non-pharmacological lifestyle modifications such as caffeine restriction, sleep hygiene, and exercise may suffice for mild cases, pharmacological treatments including dopaminergic agents, alpha-2-delta calcium channel ligands, and opioids are preferred in moderate to severe cases. However, since these chronic drug therapies aimed at relieving symptoms can lead to significant side effects such as "augmentation" (worsening of symptoms paradoxically with increased dosage), the recurrence of complaints in the morning (rebound), and impulse control disorders, it is of critical importance to individualize the treatment based on the patient's age, comorbidities, and minimum dosage adjustments.
Referanslar
Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord. 2011 Jan;26(1):114-120. doi: 10.1002/mds.23430
Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005 Jun 13;165(11):1286-1292. doi: 10.1001/archinte.165.11.1286.
Demir AU, Ardıc S, Fırat H, et al. Prevalence of sleep disorders in the Turkish adult population epidemiology of sleep study. Sleep and Biological Rhytmes. 2015;13:298-308.
Altunayoglu Cakmak V, Koc B, Nuhoglu I, et al. Prevalence of restless legs syndrome in Trabzon in the northeast Black Sea Region of Turkey: co-morbidities, socioeconomic factors and biochemical parameters. Neurol Res. 2015 Sep;37(9):751-762. doi: 10.1179/1743132815Y.0000000058.
Ferri R, Lanuzza B, Cosentino FI, et al. A single question for the rapid screening of restless legs syndrome in the neurological clinical practice. Eur J Neurol. 2007;14:1016-1021. doi: 10.1111/j.1468-1331.2007.01862.x.
International Restless Leg Syndrome Study Group. 2012 Revised IRLSSG diagnostic criteria for RLS. Rochester, USA: IRLSSG, 2012. Available online at http://irlssg.org/diagnostic-criteria/ [Accessed 10 May 2016].
Garcia-Borreguero D, Williams AM. An update on restless legs syndrome (Willis-Ekbom disease): clinical features, pathogenesis and treatment. Curr Opin Neurol. 2014;27:493–501. doi: 10.1097/WCO.0000000000000117.
Wijemanne S, Jankovic J. Restless legs syndrome: clinical presentation diagnosis and treatment. Sleep Med. 2015;16:678-690. doi: 10.1016/j.sleep.2015.03.002.
Daubian-Nose P, Frank MK, Esteves AM. Sleep disorders: a review of the interface between restless legs syndrome and iron metabolism. Sleep Sci. 201;7:234-237. doi: 10.1016/j.slsci.2014.10.002.
Gupta R, Dhyani M, Kendzerska T, et al. Restless legs syndrome and pregnancy: prevalence, possible pathophysiological mechanisms and treatment. Acta Neurol Scand. 2016;133:320-329. doi: 10.1111/ane.12520.
Ferri R. The time structure of leg movement activity during sleep: the theory behind the practice. Sleep Med. 2012 Apr;13(4):433-441. doi: 10.1016/j.sleep.2011.10.027.
Klingelhoefer L, Cova I, Gupta S, et al. A review of current treatment strategies for restless legs syndrome (Willis–Ekbom disease). Clin Med. 2014;14:520-524. doi: 10.7861/clinmedicine.14-5-520.
Stiasny-Kolster K, Kohnen R, Moller JC, et al. Validation of the “L-DOPA test” for diagnosis of restless legs syndrom. Mov Disord. 2006;21:1333–1339. doi: 10.1002/mds.20969.
Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121-132. doi: 10.1016/s1389-9457(02)00258-7.
Hoque R, Chesson AL Jr. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis . J Clin Sleep Med. 2010;679-683.
Hening W, Walters AS, Allen RP et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5237-5246. doi: 10.1016/j.sleep.2004.03.006.
Stevens MS. Restless legs syndrome/Willis-Ekbom disease morbidity: burden, quality of life, cardiovascular aspects, and sleep. Sleep Med Clin. 2015;10:369-373. doi: 10.1016/j.jsmc.2015.05.017.
Klingelhoefer L, Bhattacharya K, Reichmann H. Restless legs syndrome. Clin Med (Lond). 2016 Aug;16(4):379-382. doi: 10.7861/clinmedicine.16-4-379
Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-530. doi: 10.1016/j.sleep.2007.03.022.
Garcia-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev. 2010;14:339-346. doi: 10.1016/j.smrv.2009.11.006.
Hoque R, Chesson AL. Jr. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med. 2010;679-683.
Trenkwalder C, Hogl B, Benes H, et al. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med. 2008;9:572-574. doi: 10.1016/j.sleep.2007.07.020.
Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology. 1993;43:445. doi: 10.1212/wnl.43.2.445.
Cornelius JR, Tippmann-Peikert M, Slocumb NL, et al. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33:81-87.
Schreglmann SR, Gantenbein AR, Eisele G, et al. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18:207-209. doi: 10.1016/j.parkreldis.2011.10.010.
